Every material Form 8-K Adaptive Biotechnologies Corp has filed with the SEC since June 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, down 11% from the prior-year quarter, and net income attributable to the company of $2.9 million, or $0.02 per share, compared with $9.5 million, or $0.06 per share, a year earlier. The company raised its full-year 2026 MRD revenue guidance to $276 million to $286 million, while MRD revenue grew 28% in the quarter. Shareholders face lower reported revenue and profit this quarter, offset by the higher MRD outlook.
Q3 2026 revenue was $83.9 million, down 11% from $94.0 million in Q3 2025; MRD revenue rose 28% to $72.6 million
Net income attributable to Adaptive was $2.9 million ($0.02 per share), versus $9.5 million ($0.06 per share) in Q3 2025
Full-year 2026 MRD revenue guidance raised to $276 million to $286 million, from $268 million to $278 million
Total company operating expenses expected at approximately $350 million, versus the prior range of $350 million to $355 million
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, up 22% from a year earlier, and raised its full-year 2026 MRD revenue guidance to $268 million to $278 million. The net loss widened to $39.9 million from $25.6 million, including a $23.7 million loss on the settlement of the OrbiMed Purchase Agreement, and Chief Scientific Officer Harlan Robins is moving to a strategic consultant role.
Q2 2026 revenue was $71.6 million; MRD revenue rose 33% to $66.2 million, while Immune Medicine revenue fell 40% to $5.4 million.
Net loss attributable to the company was $39.8 million, or $0.25 per share, versus $25.6 million, or $0.17 per share, a year earlier.
Full-year 2026 MRD revenue guidance rose to $268 million to $278 million from $260 million to $270 million; total operating expense guidance was narrowed to $350 million to $355 million from $350 million to $360 million.
On July 24, 2026, Chief Scientific Officer and co-founder Dr. Harlan Robins decided to move to a strategic consultant role; a consulting agreement is expected.
Adaptive Biotechnologies issued $345 million of 0% convertible senior notes due 2031 on June 22, 2026, including an additional $45 million exercised by the initial purchasers. The company used $156.9 million of the net proceeds to repay its OrbiMed revenue interest purchase agreement, which ends its quarterly revenue-based payments to OrbiMed, and used part of the proceeds for a share repurchase and a capped call transaction.
Notes issued June 22, 2026: $345 million principal, including the $45 million option exercised June 17, 2026; net proceeds of about $334.5 million
$156.9 million used to repay all obligations under the OrbiMed Purchase Agreement, with the revenue interests terminated
Initial conversion price of about $24.11 per share, a 40.0% premium over the $17.22 closing price on June 16, 2026; notes mature July 1, 2031
About $25.0 million used to repurchase 1,451,800 shares of common stock in privately negotiated transactions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Adaptive Biotechnologies Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →